Current strategies for immunotherapy of renal cell carcinoma

✍ Scribed by R. Heicappell; R. Ackermann

• Publisher: Springer-Verlag
• Year: 1991
• Tongue: English
• Weight: 672 KB
• Volume: 9
• Category: Article
• ISSN: 0724-4983
• DOI: 10.1007/bf00182841

✦ Synopsis

Therapy for disseminated renal cell carcinoma (RCC) is a major problem, as RCC is almost completely resistant to standard therapeutic approaches such as chemotherapy or radiotherapy. The search for innovative strategies has led to new concepts based on the assumption that the cellular or soluble mediators of the immune system can be rendered cytotoxic or cytostatic for RCC.

The near-unlimited availability of genetically engineered, recombinant, soluble mediators of the immune response, the cytokines, has led to numerous clinical studies for therapy of RCC. Of all approaches under study, protocols employing interleukin-2 alone or in combination with other cytokines or chemotherapeutic drugs appear to be most promising. Despite much effort in this field, all protocols mentioned in this review concern therapies under study rather than established regimens.